Arnberg 1998.
| Study characteristics | ||
| Methods | Placebo‐controlled, not blinded, industry and public‐sponsored, single‐center trial | |
| Participants | Adults; mixed tumors; ANC < 1 x 109/L | |
| Interventions | GM‐CSF (not specified) 5.5 mcg/kg SC ATB: Many different antibiotics |
|
| Outcomes | Overall mortality Bone and joint pain or flu‐like symptoms Deep vein thrombosis | |
| Notes | Hospital discharge criteria: not reported | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | We were not able to assess the adequacy of method of sequence generation based on the information provided in the article |
| Allocation concealment (selection bias) | Unclear risk | We were not able to assess the adequacy of allocation concealment based on the information provided in the article |
| Blinding (performance bias and detection bias) All outcomes | Low risk | Double blinding was employed |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | We were not able to assess who were blinded based on the information provided in the article |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | We were not able to assess the outcomes for which blinding was employed based on the information provided in the article |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | ITT analysis used, withdrawals are described |
| Other bias | Unclear risk | Prespecified values of sample size, alpha and beta errors were not provided |